MENU

Fox Chase Adds Director of Translational Medicine Operations

January 23, 2018

PHILADELPHIA (JANUARY 23, 2018) – Fox Chase Cancer Center has hired Attila Seyhan, PhD, for the newly created position of Director of Translational Medicine Operations.

Dr. Seyhan will work closely with Wafik S. El-Deiry, MD, PhD, FACP, Deputy Cancer Center Director for Translational Research, to manage and promote multiple initiatives, including development of investigator-initiated clinical trials and other translational protocols, protocol writing and manuscript preparation, organization of translational medicine events, support for translational requests for application (RFAs), and grant preparation and submissions. He also will work with industry to follow through on investigator-initiated basic and translational letters of intent (LOIs) and concepts. This work will involve collaboration with clinicians, scientists, regulatory personnel, administrators, tech transfer office staff, the grants management office, institutional review board (IRB), institutional advancement, and external entities.

A molecular biologist by training, Dr. Seyhan has more than 16 years of experience in drug, target, and biomarker discovery and development, as well as preclinical and clinical translational research, focused on diabetes and metabolic diseases, cancer, inflammation and immunology, molecular virology, and rare genetic diseases.

His most recent position was Associate Professor at the Translational Research Institute for Metabolism and Diabetes at Florida Hospital in Orlando FL and Adjunct Associate Professor at Sanford Burnham Prebys Medical Discovery Institute, in Orlando (Lake Nona), FL. In addition, he served as a research affiliate in the department of chemical engineering at Massachusetts Institute of Technology in Boston.

In addition to academia, Dr. Seyhan has spent significant time in the pharmaceutical and biotechnology industries, having served in leading roles as Senior Principal Scientist at Pfizer Pharmaceuticals in Cambridge, Mass., Principal Scientist and Head of Functional Genomics at Wyeth Pharmaceuticals in Collegeville, PA, Senior scientist II at OpenBiosystems/Thermo Fisher in Huntsville, AL., Dharmacon/Thermo Fisher in Lafayette, CO., and SomaGenics, Inc., in Santa Cruz, CA.

Dr. Seyhan has authored or co-authored more than 35 publications and has more than nine U.S. patents to his credit. He has successfully authored grants totaling $6.2M and won several awards, including the Young Investigator Award at the Symposium on RNA Biology III and Pfizer Excellence Awards for contributions toward the Biomarkers of Lupus Disease Study. He earned his PhD in biological sciences from Michigan Technological University on a NATO Science Fellowship.

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. 
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase